We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 7.59 | 7.68 | 7.69 | 7.59 | 7.66 | 2,551,609 | 21:30:14 |
From May 2021 to May 2024
By Pietro Lombardi
Bayer AG has reached an agreement to buy research and development company Noria Therapeutics Inc. and its subsidiary PSMA Therapeutics Inc. in a move that broadens its prostate cancer portfolio.
The target companies, based in New York, have exclusive global rights to technology licensed from Weill Cornell Medicine and Johns Hopkins University, the German pharmaceutical and chemical conglomerate said Thursday.
Financial details of the deal weren't disclosed.
Write to Pietro Lombardi at pietro.lombardi@wsj.com; @pietrolombard10
(END) Dow Jones Newswires
June 03, 2021 08:28 ET (12:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
